Pricing Log in Create free account
Sunday 11 October 2026 Export all GILD data to Excel Powerpack

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

151.17 4.07 +2.77%
Market cap
$182.4B
P/E
0.0×
Fwd P/E
−46.2×
Dividend yield
2.15%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Gilead Sciences, Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:13 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2025: 38 added · 29 removed · 32 modified; 6 with only figures updated

99 more changes in this Item, word by word, in Powerpack.

Powerpack